Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444880 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
A Phase 2 study of SMARCB1-Deficient Malignancies, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06444880 is a Phase 2 study of SMARCB1-Deficient Malignancies that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06444880, a Phase 2 study of SMARCB1-Deficient Malignancies, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Ubamatamab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-10-09 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06444880
The ClinicalTrials.gov registry entry for NCT06444880 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SMARCB1-Deficient Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06444880 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06444880 about?
NCT06444880 is a clinical study titled "Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies". To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
What is the current status of trial NCT06444880?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-10-09. Estimated completion is 2028-07-31.
What conditions does trial NCT06444880 study?
This clinical trial studies the following conditions: SMARCB1-Deficient Malignancies.
What interventions are being tested in trial NCT06444880?
The interventions under investigation include: Cemiplimab (DRUG), Ubamatamab (DRUG).
Who is sponsoring clinical trial NCT06444880?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06444880 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.